Avadel Specialty Pharmaceuticals reports $17,757 net loss for June

By Caroline Salls

Pittsburgh, Aug. 1 – Avadel Specialty Pharmaceuticals, LLC reported $17,757 of net income for June on negative $120,615 in net product sales, according to its monthly operating report filed Thursday with the U.S. Bankruptcy Court for the District of Delaware.

In comparison, Avadel posted a $526,111 net loss for May on zero net product sales.

The company had $706,822 in cash and cash equivalents as of June 30, down from $77,189 at the end of May.

Avadel Pharmaceuticals is a Dublin-based specialty pharmaceutical company. The company filed bankruptcy on Feb. 6 under Chapter 11 case number 19-10248.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.